



Supplementary Figure 1. Chromosome 1p haplotypes in family AH. Haplotypes were determined by SNP microarrays. A indicates the variant allele and G the reference allele at genomic position chr1:24125191 (hg19), corresponding to GALE p.R51W (c.C151T). SNP alleles are indicated 1 or 2. The 3.78MB region of homozygosity shared by all affected individuals were bounded by rs4649009 and rs 11247639, based recombination events in relatives III.6, III.16, and III.18.

whole genome



Supplementary Figure 2. Homozygosity mapping. At each chromosomal position, histograms indicate the number of affected (red) and unaffected (green) individuals homozygous for the same allele. A) Whole genome overview. Chromosomes 1-23 are numbered top to bottom (left) then bottom to top (right). Blue box indicates the region enlarged in part B. B) Enlarged view of chromosome 1p. The 3.76 MB region between the dashed lines is the only region genome wide in which all affected individuals, and no unaffected individuals, share homozygosity for the same alleles.

Α

Β



5' GCCACAAATAGCTGT 3'

7 bp sequence flanking intergenic variant

Supplementary Figure 3. Predicted transcription factor binding sites at rs565347299.

Position weight matrices for transcription factors predicted to bind the region surrounding the intergenic variant upstream of *RUNX3*. Matrices based on the JASPAR CORE 2018 database.



Supplementary Figure 4. NAD+ binding to GALE variant proteins.

Protein samples were excited at 350 nm and emission spectra collected at 400-500 nm. Fluorescence +/- SD in RFU is reported for each variant. For each variant protein, each data point is the average of three independent experiments.



Supplementary Figure 5. Complementation by *GALE* **alleles in yeast following galactose challenge.** *S. cerevisiae* with deletion of endogenous *GALE* was complemented with empty vector, on normal human GALE (WT), or human GALE R51W. Absorbance at 660 nm was measured every 30 min. Experiment performed in biological triplicate. A) Growth assay with no galactose in media B) Growth assay with 0.05% galactose in media.



Supplementary Figure 6. GALE shRNA knockdown efficiency.

Real-time qPCR was performed in 293T cells with GALE TaqMan probe and normalized to GAPDH signal with ddCT analysis. Data are plotted as average fold expression + SD compared to luciferase control. Each experiment was run in quadruplicate.



Supplementary Figure 7. Megakaryocyte proliferation in liquid culture for shRNA knockdown of GALE. Cord-blood-derived CD34+ cells treated with control or *GALE* shRNA viruses were sorted to collect successfully transduced cells. For each condition, 500,000 cells were plated in liquid culture under megakaryocyte growth conditions and cells counted on days 0, 3, 5, and 7. Top and bottom graphs represent counts from two independent experiments.

Supplementary Tables

	Hemoglobin		WBC		
Patient	(g/dL)	MCV (fL)	(x10^9/L)	ANC	PLT
III-1	8.2	81	4	0.8	8
III-3	8.7	83	4.2	0.6	10
III-11	7.9	61	3	1.8	16
III-16	8.5	85	4.2	1.2	15
III-18	10.5	86	4.3	1	50
IV-1	12.1	81	8.8	1	44

 Table S1. Complete Blood Counts.

MCV: mean corpuscular volume, WBC: white blood count, ANC: absolute neutrophil count, PLT: platelet

Table S2. Gene expression measured by RNA-Seq for *RPL11* and *RUNX3*. Samples were prepared in duplicate. For each sample, Z scores were calculated compared to nine control samples. LIN28A expression was not detectable in RNA from lymphoblasts.

Gene	Proband	Proband	Mother	Mother	Father	Father
	replicate1	replicate2	replicate1	replicate2	replicate1	replicate2
RPL11	-0.81	-0.56	-0.33	-0.44	-0.41	-0.99
RUNX3	0.83	0.63	-0.11	-1.12	0.19	1.27

Table S3. Rare variants from whole genome sequencing located in the homozygous region shared by all affected individuals in family AH, and either conserved (GERP >2.0) or in proximity to a gene possibly implicated in bone marrow failure.

Chr Coordinate Ref Var Type Gene Gerp S FFB Encode Chipseq DNasel 1 24,020,197 G A intronic RPL11 -1.3 - Enhancer HEY1 5 1 24,125,191 G A missense GALE +4.8 - Insulator 5916),CTCF 20 1 25,184,753 A G intergenic RUNX3 (dist=41249) +0.2 - Weak Txn - - 1 25,186,263 - ATATT intergenic (dist=3739) indel - Weak Txn - - 1 25,187,920 C T intergenic (dist=38082) +0.6 - Txn - - 1 25,282,297 G A intronic RUNX3 -3.0 - Transition - 13 1 25,252,493 G A intronic RUNX3 -2.9
Chr Coordinate Ref Var Type Gene Gerg S HMM Chipseq DNasel 1 24,020,197 G A intronic RPL11 -1.3 - Enhancer HEY1 5 1 24,020,197 G A missense GALE +4.8 - Insulator Strong 1 25,184,753 A G intergenic (dist=41249) +0.2 - Weak Txn - - - 1 25,186,263 - ACACA RUNX3 idist=3739) indel - Weak Txn - - - 1 25,186,263 - ATATT intergenic (dist=38082) +0.6 - Weak Txn - - - 1 25,280,541 C T intronic RUNX3 -3.0 - Transition - 13 1 25,250,541 C T intronic RUNX3 <
1 24,020,197 G A intronic RPL11 -1.3 - Enhancer HEY1 5 1 24,125,191 G A missense GALE +4.8 - Insulator 5916),CTCF 20 1 25,184,753 A G intergenic RUNX3 (dist=41249) +0.2 - Weak Txn - - 1 25,184,753 A G intergenic (dist=39739) indel - Weak Txn - - 1 25,186,263 - ATATT intergenic (dist=39739) indel - Weak Txn - - 1 25,186,263 - ATATT intergenic (dist=39739) indel - Weak Txn - - 1 25,186,263 - A intronic RUNX3 -3.0 - Txn - - 1 25,280,541 C T intronic RUNX3 -0.7 - Enhancer - - - - - - -<
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
1 25,184,753 A G intergenic RUNX3 (dist=41249) +0.2 - Weak Txn - - 1 25,184,753 A G intergenic (dist=41249) +0.2 - Weak Txn - - 1 25,186,263 - ACACA CACAT RUNX3 indel - Weak Txn - - 1 25,187,920 C T intergenic RUNX3 idist=38082) +0.6 - Weak Txn - - 1 25,242,297 G A intronic RUNX3 -3.0 - Transition - 13 1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer - - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer - - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer - 7 1 25,252,493 G A intron
1 25,186,263 - ATATT intergenic (dist=39739) indel - Weak Txn - - 1 25,186,263 - ATATT intergenic (dist=39739) indel - Weak Txn - - 1 25,187,920 C T intergenic (dist=38082) +0.6 - Weak Txn - - 1 25,242,297 G A intronic RUNX3 -3.0 - Txn - 13 1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer - - - 1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer - - - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer Pol2-4H8 - 1 25,324,183 A G intergenic (dist=32682) +4.3) Enhancer - 7 1 25,905,634 C
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
1 25,242,297 G A intronic RUNX3 -3.0 - Transition - 13 1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer - - - - - - - 13 1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer -
1 25,250,541 C T intronic RUNX3 +0.7 - Enhancer - - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer Pol2-4H8 - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer Pol2-4H8 - 1 25,324,183 A G intergenic (dist=32682) +4.3) Enhancer - 7 1 25,905,634 C T intergenic (dist=32682) +4.3) Enhancer - 7 1 25,905,634 C T intergenic (dist=38325) +2.2 - om/lo - - 1 26,068,576 G A intronic MAN1C1 +2.1 - Repressed - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - om/lo - - 1 26,258,357 T C inte
1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer Pol2-4H8 - 1 25,252,493 G A intronic RUNX3 -2.9 - Enhancer Pol2-4H8 - 1 25,324,183 A G intergenic (dist=32682) +4.3) Enhancer - 7 1 25,905,634 C T intergenic (dist=38325) +2.2 - om/lo - - 1 26,068,576 G A intronic MAN1C1 +2.1 - Repressed - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - om/lo - - 1 26,258,357 T C intergenic LIN28A Heterochr - - -
1 25,324,183 A G intergenic (dist=32682) +4.3) Enhancer - 7 1 25,905,634 C T intergenic (dist=38325) +2.2 - om/lo - - 1 26,068,576 G A intergenic MAN1C1 +2.1 - Repressed - - 1 26,068,577 G A intergenic (dist=27901) -1.0 - Repressed - - 1 26,258,357 T C intergenic LIN28A Heterochr - - - 1 26,258,357 T C intergenic LIN28A - Heterochr - -
1 25,905,634 C T intergenic MAN1C1 (dist=38325) +2.2 - Heterochr om/lo - - 1 26,068,576 G A intronic MAN1C1 +2.1 - Repressed - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - om/lo - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - om/lo - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - om/lo - -
1 26,068,576 G A intronic MAN1C1 +2.1 - Repressed - - 1 26,258,357 T C intergenic (dist=27901) -1.0 - Heterochr om/lo - - 1 26,258,357 T C intergenic LIN28A - Heterochr - -
1 26,258,357 T C intergenic PAFAH2 (dist=27901) -1.0 Heterochr om/lo - 1 26,258,357 T C intergenic LIN28A Heterochr -
LIN28A Heterochr
1 26,728,707 C I intergenic (dist=8562) -2.4 - om/lo STAT3 -
1 27,084,517 T C intronic ARID1A +3.8 - Elongation
1 27 320 968 C T UITP3 TENP1 +2.3 Poised (SC-34508), Poised (SC-34508), Poised (SC-34508),
1 27,625,246 C T intronic WDTC1 +3.0 - Weak Typ - 5

	GALE F	Proteins		
Substrate	wт	R51W	V94M	D103G
UDP-gal	0.426	0.235	0.004	0.201
UDP-gal	0.431	0.138	0.003	0.28
UDP-gal	0.434	0.137	0.004	0.179
UDP-galNAc	0.305	0.121	0.017	0.153
UDP-galNAc	0.296	0.114	0.016	0.143
UDP-galNAc	0.287	0.114	0.015	0.121
UDP-galNAc	0.315	0.117	0.012	0.157

Table S4. Fraction product (UDP-glc or UDP-glcNAc) from GALE enzyme assays

Table S5. Cell proliferation under megakaryocyte growth conditions after shRNA knockdown

		Days after seeding 500,000 cells from each treatment			ch treatment
	Expt	0	3	5	7
GALE1	1	500,000	2,180,000	1,600,000	1,680,000
GALE2	1	500,000	2,810,000	3,289,000	1,880,000
Control	1	500,000	2,440,000	3,989,999	2,826,700
GALE1	2	500,000	388,889	266,667	333,333
GALE2	2	500,000	1,077,778	600,000	388,889
Control	2	500,000	1,322,222	1,555,556	1,633,333

			total	small	medium	large	Prop	P vs
			colonies				large	
shRNA	Expt	Rep	counted	(3-20	(21-49	(>50	colonies	control
				cells)	cells)	cells)		
GALE1	1	Α	170	85	56	29	0.171	
GALE1	1	В	137	57	42	38	0.277	
GALE1	2	А	278	124	83	71	0.255	
GALE1	2	В	401	179	127	95	0.237	
GALE1	total		986	445	308	233	0.235	0.008
GALE2	1	А	145	45	53	47	0.324	
GALE2	1	В	125	22	46	57	0.456	
GALE2	2	Α	313	89	114	110	0.351	
GALE2	2	В	325	78	101	146	0.449	
GALE2	total		908	234	314	360	0.395	0.0005
Control	1	Α	254	172	74	8	0.031	
Control	1	В	246	168	62	16	0.065	
Control	2	Α	318	203	76	39	0.123	
Control	2	В	418	257	96	65	0.156	
Control	total		1236	800	308	128	0.094	

 Table S6. Size Distribution of Megakaryocyte Colonies

 Table S7. Chromatographic Pump Gradient parameters

Pressure limits: low: 0 psi, high: 15,000 psi					
Step	Time (min)	Flow (mL/min)	%A	%В	Curve
1	(initial)	0.400	10.0	90.0	(initial)
2	5.00	0.400	20.0	80.0	6
3	5.50	0.400	40.0	60.0	6
4	6.50	0.400	40.0	60.0	6
5	9.00	0.400	10.0	90.0	1

Run time: 9.0 min Seal wash: 5 min Pressure limits: low: 0 psi, high: 15,000 psi

Solvent A = H_2O + 10mM Ammonium Formate + 0.125% (v/v) Formic Acid (FA) (Fisher UPLCgrade)

Solvent B = 95:5 Acetonitrile: H_2O + 10mM Ammonium Formate + 0.125% (v/v) FA

Strong Needle Wash = $95:5 \text{ ACN}: H_2O$

Weak Needle Wash = $90:10 H_2O:ACN$

Table S8. Mass Spectrometer Tuning Parameters

Collision energy for different multiple-reaction monitoring (MRM) transitions

Compound	Parent	Daughter		
Name	(m/z)	(m/z)	Cone (V)	Collision (V)
UDP-gal-241	564.90	241.00	35	29
UDP-glc-241	564.90	241.01	35	29
UDP-gal-280	564.90	279.90	35	27
UDP-glc-280	564.90	279.91	35	27
UDP-gal-403	564.90	403.00	35	22
UDP-glc-403	564.90	403.01	35	22
UDP-galNAc-159	606.00	159.00	39	44
UDP-glcNAc-159	606.00	159.01	39	44
UDP-galNAc-273	606.00	272.90	39	32
UDP-glcNAc-273	606.00	272.91	39	32
UDP-galNAc-282	606.00	282.00	39	27
UDP-glcNAc-282	606.00	282.01	39	27
UDP-galNAc-385	606.00	384.90	39	24
UDP-glcNAc-385	606.00	384.91	39	24
UDP-galNAc-403	606.00	403.00	39	23
UDP-glcNAc-403	606.00	403.01	39	23

Table S9. Sugar Retention Times

Sugar	Retention Time (min.)
UDP-glc	4.37
UDP-gal	4.60
DP-glcNAc	4.76
UDP-galNAc	4.98